BioSpace News Archive

Immunocore Holdings plc announced the pricing of $350.0 million aggregate principal amount of 2.50% convertible senior notes due 2030 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Defender Pharmaceuticals, Inc. (the “Company” or “Defender”) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s New Drug Application (NDA) for intranasal scopolamine (DPI-386) for the prevention of nausea and vomiting induced by motion in adults.

Endogenex, Inc. announced that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to initiate a clinical study of the ReCET System for the treatment of T2D in adult patients, inadequately controlled by non-insulin, glucose lowering medications.

Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, February 13, 2024, to report its financial results for the third quarter ended December 31, 2023, and provide a business update.

BioStem Technologies Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, highlights its 2023 accomplishments and provides a business update.

Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

STERIS plc announced that the Company will distribute a quarterly interim dividend of $0.52 per share.

Tampa General Hospital celebrated excellent results from its first transcatheter mitral valve implant, making it the first and only hospital in the Southeast to complete a mitral valve replacement procedure via a catheter.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.